• Bioniche Life Sciences Inc., of Belleville, Ontario, accepted a $20 million, five-year term loan provided by Capital Royalty LP. The terms include a 15 percent interest rate, with a portion deferred and capitalized for the first three years, as well as an additional 2 percent royalty interest on product sales during the term of the loan.

• Marshall Edwards Inc., of San Diego, is raising up to $7.6 million in a rights offering. Holders of the biotech's common stock and Series A warrants will be eligible to purchase one unit for each share of stock owned or issuable, with each unit consisting of one-half of a common share and a warrant to purchase an additional one-quarter of a common share. For every two units purchased, stockholders will receive one share of common stock at a price of 89 cents apiece and warrants to purchase half a share at an exercise price of $1.19. Majority shareholder Novogen Ltd. plans to exercise rights for up to $4 million and distribute a portion of its rights to its shareholders, subject to shareholder approval. Proceeds will support clinical trials of cancer metabolism programs ME-344 and ME-143.

• XTL Biopharmaceuticals Ltd., of Herzeliya, Israel, raised $2.4 million in a private placement and an additional $1.1 million through the exercise of warrants. The placement was priced at 42 cents per American Depositary Receipt (ADR), a 30 percent discount to Friday's closing price of 60 cents per ADR, while the warrants were priced at 56 cents per ADR. Menora Mivtahim Underwriting and Management Ltd. acted as an advisor for the financing. Proceeds will support development of rHuEPO for multiple myeloma.